These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 566853)

  • 21. Fibroadenoma in oral contraceptive users: a histopathologic evaluation of epithelial atypia.
    LiVolsi VA; Stadel BV; Kelsey JL; Holford TR
    Cancer; 1979 Nov; 44(5):1778-81. PubMed ID: 498048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The patho-epidemiology of benign proliferative epithelial disorders of the female breast.
    Cook MG; Rohan TE
    J Pathol; 1985 May; 146(1):1-15. PubMed ID: 3891937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oral contraception and risk of cancer. Epidemiological aspects of breast and gynecological cancers].
    Plu-Bureau G
    Rev Prat; 1995 Dec; 45(19):2441-4. PubMed ID: 8571057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral contraceptives and the risk of death from breast cancer.
    Wingo PA; Austin H; Marchbanks PA; Whiteman MK; Hsia J; Mandel MG; Peterson HB; Ory HW
    Obstet Gynecol; 2007 Oct; 110(4):793-800. PubMed ID: 17906011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer epidemiology.
    Kelsey JL; Berkowitz GS
    Cancer Res; 1988 Oct; 48(20):5615-23. PubMed ID: 3048646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
    Strom BL; Berlin JA; Weber AL; Norman SA; Bernstein L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone KE; Marchbanks PA; Simon MS; Ursin G; Weiss LK; Spirtas R
    Contraception; 2004 May; 69(5):353-60. PubMed ID: 15105056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the health risks and benefits of contraceptive choices.
    Kost K; Forrest JD; Harlap S
    Fam Plann Perspect; 1991; 23(2):54-61. PubMed ID: 2060612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. At pill's 30th birthday, breast cancer question is unresolved.
    Althaus FA; Kaeser L
    Fam Plann Perspect; 1990; 22(4):173-6. PubMed ID: 2226748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral contraceptive use and BRCA penetrance: a case-only study.
    Pasanisi P; Hédelin G; Berrino J; Chang-Claude J; Hermann S; Steel M; Haites N; Hart J; Peled R; Gafà L; Leggio L; Traina A; Amodio R; Primic-Zakelj M; Zadnik V; Veidebaum T; Tekkel M; Berrino F
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2107-13. PubMed ID: 19549808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
    Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
    Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral contraceptive use and fibrocystic breast disease among pre- and postmenopausal women.
    Berkowitz GS; Kelsey JL; LiVolsi VA; Holford TR; Merino MJ; Ort S; O'Connor TZ; Goldenberg IS; White C
    Am J Epidemiol; 1984 Jul; 120(1):87-96. PubMed ID: 6741927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exogenous hormone use and fibrocystic breast disease by histopathologic component.
    Berkowitz GS; Kelsey JL; LiVolsi VA; Merino MJ; Holford TR; Hildreth NG; Ort S; O'Connor TZ; White C
    Int J Cancer; 1984 Oct; 34(4):443-9. PubMed ID: 6490201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From the NIH: Oral contraceptive use no protection against cancer risk-associated fibrocystic breast disease.
    JAMA; 1979 Jan; 241(1):24. PubMed ID: 758486
    [No Abstract]   [Full Text] [Related]  

  • 35. Granulomatous mastitis. A review of 5 cases.
    Cohen C
    S Afr Med J; 1977 Jul; 52(1):14-6. PubMed ID: 560723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrocystic disease in women receiving oral contraceptive hormones.
    Fechner RE
    Cancer; 1970 Jun; 25(6):1332-9. PubMed ID: 5422909
    [No Abstract]   [Full Text] [Related]  

  • 37. Benign breast disease and oral contraceptive use.
    Janerich DT; Glebatis DM; Dugan JM
    JAMA; 1977 May; 237(20):2199-201. PubMed ID: 576904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are there differences in breast tissue as a result of hormone replacement therapy? Can BEST imaging distinguish these differences?
    Fleming RM
    Integr Cancer Ther; 2003 Sep; 2(3):229-34. PubMed ID: 15035885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An epidemiologic study of fibrocystic breast disease with reference to ductal epithelial atypia.
    Pastides H; Kelsey JL; Holford TR; LiVolsi VA
    Am J Epidemiol; 1985 Mar; 121(3):440-7. PubMed ID: 4014134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral contraceptives and benign breast disease.
    Hislop TG; Threlfall WJ
    Am J Epidemiol; 1984 Aug; 120(2):273-80. PubMed ID: 6465125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.